Elena Arbelo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7383981/publications.pdf

Version: 2024-02-01

177	19,585	43	129
papers	citations	h-index	g-index
191	191	191	14290
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Accuracy of standard bipolar amplitude voltage thresholds to identify late potential channels in ventricular tachycardia ablation. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 15-25.	0.6	5
2	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2â€"care pathways, treatment, and follow-up. European Heart Journal, 2022, 43, 1059-1103.	1.0	111
3	Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit: a prospective multicentre study. Europace, 2022, 24, 774-783.	0.7	5
4	Outcomes of conduction system pacing compared to right ventricular pacing as a primary strategy for treating bradyarrhythmia: systematic review and meta-analysis. Clinical Research in Cardiology, 2022, 111, 1198-1209.	1.5	18
5	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace, 2022, 24, 71-164.	0.7	370
6	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. Europace, 2022, 24, 165-172.	0.7	20
7	Clinical impact of rare variants associated with inherited channelopathies: a 5-year update. Human Genetics, 2022, 141, 1579-1589.	1.8	11
8	The prevalence of left and right bundle branch block morphology ventricular tachycardia amongst patients with arrhythmogenic cardiomyopathy and sustained ventricular tachycardia: insights from the European Survey on Arrhythmogenic Cardiomyopathy. Europace, 2022, 24, 285-295.	0.7	7
9	European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology. European Journal of Preventive Cardiology. 2022. 29. 1060-1071.	0.8	25
10	Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation Ablation long-term (AFA LT) registry. International Journal of Cardiology, 2022, 346, 19-26.	0.8	2
11	Late gadolinium enhancementâ€MRI determines definite lesion formation most accurately at 3 months post ablation compared to later time points. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 72-82.	0.5	10
12	Clinical Genetics of Inherited Arrhythmogenic Disease in the Pediatric Population. Biomedicines, 2022, 10, 106.	1.4	9
13	Septal flash correction with Hisâ€Purkinje pacing predicts echocardiographic response in resynchronization therapy. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 374-383.	0.5	4
14	The 2020 ESC atrial fibrillation guidelines for atrial fibrillation catheter ablation, CABANA, and EAST. Europace, 2022, 24, ii3-ii7.	0.7	6
15	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
16	Discerning the Ambiguous Role of Missense TTN Variants in Inherited Arrhythmogenic Syndromes. Journal of Personalized Medicine, 2022, 12, 241.	1.1	2
17	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1â€"epidemiology, pathophysiology, and diagnosis. Cardiovascular Research, 2022, 118, 1385-1412.	1.8	27
18	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nature Genetics, 2022, 54, 232-239.	9.4	55

#	Article	IF	CITATIONS
19	<i>BAG3</i> Genetic Cardiomyopathy May Overlap Fulminant Myocarditis Clinical Findings. Circulation: Heart Failure, 2022, 15, e008443.	1.6	1
20	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2â€"care pathways, treatment, and follow-up. Cardiovascular Research, 2022, 118, 1618-1666.	1.8	32
21	Brugada Syndrome in Women: What Do We Know After 30 Years?. Frontiers in Cardiovascular Medicine, 2022, 9, 874992.	1.1	5
22	Late Potential Abolition in Ventricular Tachycardia Ablation. American Journal of Cardiology, 2022, 174, 53-60.	0.7	6
23	Prevalence of Pathogenic Variants in Cardiomyopathy-Associated Genes in Myocarditis. Circulation Genomic and Precision Medicine, 2022, 15, 101161CIRCGEN121003408.	1.6	13
24	Conduction system pacing vs. biventricular pacing in patients with ventricular dysfunction and AV block. PACE - Pacing and Clinical Electrophysiology, 2022, , .	0.5	7
25	Impact of SARSâ€Covâ€2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure, 2022, 9, 2189-2198.	1.4	6
26	Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. European Heart Journal, 2022, 43, 3041-3052.	1.0	32
27	Adenosine usage during AF ablation in Europe and selected long-term findings from the ESC-EHRA EORP Atrial Fibrillation Ablation Long-Term registry. Journal of Interventional Cardiac Electrophysiology, 2021, 60, 395-406.	0.6	1
28	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. European Heart Journal Quality of Care & Dutcomes, 2021, 7, 229-237.	1.8	16
29	Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace, 2021, 23, 147-148.	0.7	47
30	HRS/EHRA/APHRS/LAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. Europace, 2021, 23, 313-313.	0.7	32
31	Accuracy of left atrial fibrosis detection with cardiac magnetic resonance: correlation of late gadolinium enhancement with endocardial voltage and conduction velocity. Europace, 2021, 23, 380-388.	0.7	52
32	Impact of centre volume on atrial fibrillation ablation outcomes in Europe: a report from the ESC EHRA EORP Atrial Fibrillation Ablation Long-Term (AFA LT) Registry. Europace, 2021, 23, 49-58.	0.7	6
33	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	1.0	5,583
34	Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace, 2021, 23, 494-495.	0.7	64
35	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58.	1.1	57
36	World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update. Global Heart, 2021, 16, 41.	0.9	39

#	Article	IF	CITATIONS
37	Malignant Arrhythmogenic Role Associated with RBM20: A Comprehensive Interpretation Focused on a Personalized Approach. Journal of Personalized Medicine, 2021, 11, 130.	1.1	4
38	Rare Variants Associated with Arrhythmogenic Cardiomyopathy: Reclassification Five Years Later. Journal of Personalized Medicine, 2021, 11, 162.	1.1	13
39	Reduction in new cardiac electronic device implantations in Catalonia during COVID-19. Europace, 2021, 23, 456-463.	0.7	25
40	Optimized singleâ€point left ventricular pacing leads to improved resynchronization compared with multipoint pacing. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 519-527.	0.5	2
41	Long-term prognosis of women with Brugada syndrome and electrophysiological study. Heart Rhythm, 2021, 18, 664-671.	0.3	13
42	Proximity to the descending aorta predicts regional fibrosis in the adjacent left atrial wall: aetiopathogenic and prognostic implications. Europace, 2021, 23, 1559-1567.	0.7	9
43	Cardiac magnetic resonance to predict recurrences after ventricular tachycardia ablation: septal involvement, transmural channels, and left ventricular mass. Europace, 2021, 23, 1437-1445.	0.7	12
44	Cardiac Resynchronization Therapy Response Is Equalized in Men and Women byÂElectricalÂOptimization. JACC: Clinical Electrophysiology, 2021, 7, 1400-1409.	1.3	2
45	Reply to the Editorâ€"Electrophysiologic study in women with Brugada Syndrome. Heart Rhythm, 2021, 18, 1039-1040.	0.3	O
46	Ventricular tachycardia burden reduction after substrate ablation: Predictors of recurrence. Heart Rhythm, 2021, 18, 896-904.	0.3	20
47	Early Identification of Prolonged QT Interval for Prevention of Sudden Infant Death. Frontiers in Pediatrics, 2021, 9, 704580.	0.9	3
48	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2021, 42, 3427-3520.	1.0	899
49	Genotype-Phenotype Correlation of <i>SCN5A</i> Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Probands. Circulation Genomic and Precision Medicine, 2021, 14, e003222.	1.6	7
50	Scar channels in cardiac magnetic resonance to predict appropriate therapies in primary prevention. Heart Rhythm, 2021, 18, 1336-1343.	0.3	30
51	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
52	Validation of multiparametric approaches for the prediction of sudden cardiac death in patients with Brugada syndrome and electrophysiological study. Revista Espanola De Cardiologia (English Ed), 2021,	0.4	1
53	Sport practice in hypertrophic cardiomyopathy: running to stand still?. International Journal of Cardiology, 2021, 345, 77-82.	0.8	12
54	Implantable Loop Recorders in Brugada syndrome: an ally?. Heart Rhythm, 2021, , .	0.3	O

#	Article	IF	Citations
55	In-hospital and 12-month follow-up outcome from the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry: sex differences. Europace, 2020, 22, 66-73.	0.7	33
56	2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 655-720.	1.0	647
57	The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope. American Heart Journal, 2020, 220, 213-223.	1.2	15
58	†Real-world†Mobservational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Europace, 2020, 22, 831-832.	0.7	18
59	Cryoballoon vs. radiofrequency lesions as detected by late-enhancement cardiac magnetic resonance after ablation of paroxysmal atrial fibrillation: a case–control study. Europace, 2020, 22, 382-387.	0.7	11
60	Ablation strategies for different types of atrial fibrillation in Europe: results of the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry. Europace, 2020, 22, 558-566.	0.7	11
61	Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries. Europace, 2020, 22, 250-258.	0.7	7
62	Update on Genetic Basis of Brugada Syndrome: Monogenic, Polygenic or Oligogenic?. International Journal of Molecular Sciences, 2020, 21, 7155.	1.8	36
63	Magnetic resonance-guided re-ablation for atrial fibrillation is associated with a lower recurrence rate: a case–control study. Europace, 2020, 22, 1805-1811.	0.7	18
64	Magnetic Resonance Imaging-Guided Fibrosis Ablation for the Treatment of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008707.	2.1	44
65	HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009007.	2.1	15
66	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation, 2020, 142, 324-338.	1.6	83
67	Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. European Heart Journal, 2020, 41, 3437-3447.	1.0	78
68	The arrhythmogenic right ventricular cardiomyopathy in comparison to the athletic heart. Journal of Cardiovascular Electrophysiology, 2020, 31, 1836-1843.	0.8	16
69	COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias. Heart Rhythm, 2020, 17, 1423-1424.	0.3	12
70	HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. Journal of the American College of Cardiology, 2020, 76, 1363-1374.	1,2	37
71	HRS/EHRA/APHRS/LAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. Heart Rhythm, 2020, 17, e255-e268.	0.3	20
72	Genetic Variants as Sudden-Death Risk Markers in Inherited Arrhythmogenic Syndromes: Personalized Genetic Interpretation. Journal of Clinical Medicine, 2020, 9, 1866.	1.0	5

#	Article	IF	Citations
73	Electromechanical delay by speckle-tracking echocardiography: A novel tool to distinguish between Brugada syndrome and isolated right bundle branch block. International Journal of Cardiology, 2020, 320, 161-167.	0.8	3
74	Ventricular scar channel entrances identified by new wideband cardiac magnetic resonance sequence to guide ventricular tachycardia ablation in patients with cardiac defibrillators. Europace, 2020, 22, 598-606.	0.7	28
75	Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. European Heart Journal, 2020, 41, 614-617.	1.0	15
76	Sudden Cardiac Death and Copy Number Variants: What Do We Know after 10 Years of Genetic Analysis?. Forensic Science International: Genetics, 2020, 47, 102281.	1.6	20
77	SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Heart Rhythm, 2020, 17, 1456-1462.	0.3	162
78	Reanalysis and reclassification of rare genetic variants associated with inherited arrhythmogenic syndromes. EBioMedicine, 2020, 54, 102732.	2.7	46
79	Pediatric Malignant Arrhythmias Caused by Rare Homozygous Genetic Variants in TRDN: A Comprehensive Interpretation. Frontiers in Pediatrics, 2020, 8, 601708.	0.9	3
80	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. European Heart Journal, 2020, 41, 1132-1140.	1.0	50
81	Brugada syndrome, Brugada phenocopy, or simply arrythmia induced by cocaine intoxication?. Emergencias, 2020, 32, 72-74.	0.6	0
82	Short QT Syndrome: A Comprehensive Genetic Interpretation and Clinical Translation of Rare Variants. Journal of Clinical Medicine, 2019, 8, 1035.	1.0	33
83	Influence of risk factors in the ESCâ€EHRA EORP atrial fibrillation ablation longâ€term registry. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1365-1373.	0.5	15
84	Ethnic differences in patients with Brugada syndrome and arrhythmic events: New insights from Survey on Arrhythmic Events in Brugada Syndrome. Heart Rhythm, 2019, 16, 1468-1474.	0.3	22
85	Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. Europace, 2019, 21, 1802-1808.	0.7	11
86	Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study. Lancet, The, 2019, 394, 1344-1351.	6.3	49
87	Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative) Tj ETQq1 1 0.78	34314 rgBT 0.4	「/Overlock 1 1
88	Out-of-hospital cardiac arrest due to idiopathic ventricular fibrillation in patients with normal electrocardiograms: results from a multicentre long-term registry. Europace, 2019, 21, 1670-1677.	0.7	34
89	Reproducibility and accuracy of late gadolinium enhancement cardiac magnetic resonance measurements for the detection of left atrial fibrosis in patients undergoing atrial fibrillation ablation procedures. Europace, 2019, 21, 724-731.	0.7	31
90	Personalized Interpretation and Clinical Translation of Genetic Variants Associated With Cardiomyopathies. Frontiers in Genetics, 2019, 10, 450.	1.1	6

#	Article	IF	Citations
91	Management of anticoagulation in patients undergoing leadless pacemaker implantation. Heart Rhythm, 2019, 16, 1849-1854.	0.3	12
92	Electrocardiographic optimization techniques in resynchronization therapy. Europace, 2019, 21, 1286-1296.	0.7	15
93	Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. European Journal of Heart Failure, 2019, 21, 690-693.	2.9	3
94	Genetic interpretation and clinical translation of minor genes related to Brugada syndrome. Human Mutation, 2019, 40, 749-764.	1.1	32
95	Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome. Journal of the American College of Cardiology, 2019, 73, 1756-1765.	1.2	53
96	Failure-free survival of the Riata implantable cardioverter-defibrillator lead after a very long-term follow-up. Indian Pacing and Electrophysiology Journal, 2019, 19, 140-144.	0.3	1
97	Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Europace, 2019, 21, 796-802.	0.7	16
98	Atrial fibrillation history impact on catheter ablation outcome. Findings from the ESCâ€EHRA Atrial Fibrillation Ablation Longâ€Term Registry. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 313-320.	0.5	9
99	Cryoballoon vs. radiofrequency ablation for atrial fibrillation: a study of outcome and safety based on the ESC-EHRA atrial fibrillation ablation long-term registry and the Swedish catheter ablation registry. Europace, 2019, 21, 581-589.	0.7	69
100	Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. Heart, 2019, 105, 244-250.	1.2	67
101	Role of copy number variants in sudden cardiac death and related diseases: genetic analysis and translation into clinical practice. European Journal of Human Genetics, 2018, 26, 1014-1025.	1.4	26
102	Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome. Heart Rhythm, 2018, 15, 1394-1401.	0.3	71
103	Improvement of Reverse RemodelingÂUsing Electrocardiogram Fusion-Optimized Intervals in CardiacÂResynchronization Therapy. JACC: Clinical Electrophysiology, 2018, 4, 181-189.	1.3	64
104	Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Heart Rhythm, 2018, 15, 716-724.	0.3	57
105	The longâ€QT syndrome and exercise practice: The neverâ€ending debate. Journal of Cardiovascular Electrophysiology, 2018, 29, 489-496.	0.8	22
106	Postprocedural LGEâ€CMR comparison of laser and radiofrequency ablation lesions after pulmonary vein isolation. Journal of Cardiovascular Electrophysiology, 2018, 29, 1065-1072.	0.8	15
107	SCN5A mutation type and topology are associated with the risk of ventricular arrhythmia by sodium channel blockers. International Journal of Cardiology, 2018, 266, 128-132.	0.8	21
108	Long-term prognosis of patients with life-threatening ventricular arrhythmias induced by coronary artery spasm. Europace, 2018, 20, 851-858.	0.7	39

#	Article	IF	CITATIONS
109	Recent Advances in Short QT Syndrome. Frontiers in Cardiovascular Medicine, 2018, 5, 149.	1.1	60
110	Delayed Gadolinium Enhancement Magnetic Resonance Imaging Detected Anatomic Gap Length in Wide Circumferential Pulmonary Vein Ablation Lesions Is Associated With Recurrence of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006659.	2.1	28
111	Present Status of Brugada Syndrome. Journal of the American College of Cardiology, 2018, 72, 1046-1059.	1.2	291
112	Preferential regional distribution of atrial fibrosis in posterior wall around left inferior pulmonary vein as identified by late gadolinium enhancement cardiac magnetic resonance in patients with atrial fibrillation. Europace, 2018, 20, 1959-1965.	0.7	47
113	Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients. Heart Rhythm, 2018, 15, 1457-1465.	0.3	65
114	A QRS axis–based algorithm to identify the origin of scar-related ventricular tachycardia in the 17-segment American Heart Association model. Heart Rhythm, 2018, 15, 1491-1497.	0.3	32
115	Electrocardiographic Assessment and Genetic Analysis in Neonates: a Current Topic of Discussion. Current Cardiology Reviews, 2018, 15, 30-37.	0.6	5
116	Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. European Heart Journal, 2017, 38, ehw564.	1.0	151
117	Brugada Syndrome and Exercise Practice: Current Knowledge, Shortcomings and Open Questions. International Journal of Sports Medicine, 2017, 38, 573-581.	0.8	16
118	Another piece of the puzzle: Assessment of mechanical dispersion by magnetic resonance in long QT syndrome. Heart Rhythm, 2017, 14, 1398-1399.	0.3	1
119	Left atrial fibrosis quantification by late gadolinium-enhanced magnetic resonance: a new method to standardize the thresholds for reproducibility. Europace, 2017, 19, 1272-1279.	0.7	103
120	Patients With Brugada Syndrome and Implanted Cardioverter-Defibrillators. Journal of the American College of Cardiology, 2017, 70, 1991-2002.	1,2	34
121	Age of First Arrhythmic Event in Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	57
122	Occupational radiation exposure in the electrophysiology laboratory with a focus on personnel with reproductive potential and during pregnancy: A European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS). Europace, 2017, 19, 1909-1922.	0.7	50
123	Large Genomic Imbalances in Brugada Syndrome. PLoS ONE, 2016, 11, e0163514.	1.1	23
124	Long-term benefit of first-line peri-implantable cardioverter–defibrillator implant ventricular tachycardia-substrate ablation in secondary prevention patients. Europace, 2016, 19, euw096.	0.7	7
125	Substrate modification or ventricular tachycardia induction, mapping, and ablation as the first step? A randomized study. Heart Rhythm, 2016, 13, 1589-1595.	0.3	57
126	European Heart Rhythm Association Young Electrophysiology Community: the future is just ahead. Europace, 2016, 18, 785-787.	0.7	2

#	Article	IF	CITATIONS
127	Status of cardiac resynchronization therapy in Catalonia, Spain: Results of the prospective multicentric study TRC-CAT. Medicina ClÂnica (English Edition), 2016, 146, 423-428.	0.1	1
128	Plasma tissue inhibitor of matrix metalloproteinase-1 a predictor of long-term mortality in patients treated with cardiac resynchronization therapy. Europace, 2016, 18, 232-237.	0.7	12
129	Regional differences in referral, procedures, and outcome after ablation for atrial fibrillation in Europe: a report from the Atrial Fibrillation Ablation Pilot Registry of the European Society of Cardiology. Europace, 2016, 18, 191-200.	0.7	13
130	Gene-Specific Therapy for Congenital Long QT Syndrome. Journal of the American College of Cardiology, 2016, 67, 1059-1061.	1.2	6
131	Monomorphic ventricular tachycardia in patients with Brugada syndrome: A multicenter retrospective study. Heart Rhythm, 2016, 13, 669-682.	0.3	67
132	Brugada syndrome: clinical and genetic findings. Genetics in Medicine, 2016, 18, 3-12.	1.1	102
133	Natural and Undetermined Sudden Death: Value of Post-Mortem Genetic Investigation. PLoS ONE, 2016, 11, e0167358.	1.1	62
134	Update on the Differential Diagnosis and Treatment of Brugada Syndrome. , 2016, , 139-172.		0
135	Genetics of inherited arrhythmias in pediatrics. Current Opinion in Pediatrics, 2015, 27, 665-674.	1.0	10
136	A Genetically Vulnerable Myocardium May Predispose to Myocarditis. Journal of the American College of Cardiology, 2015, 66, 2913-2914.	1.2	41
137	Left Atrial Tachycardia After Atrial Fibrillation Ablation: Can Magnetic Resonance Imaging Assist the Ablation?. Canadian Journal of Cardiology, 2015, 31, 104.e1-104.e3.	0.8	2
138	Ventricular Fibrillation Inducibility in the Early Repolarization Syndrome. Journal of the American College of Cardiology, 2015, 65, 160-162.	1.2	2
139	Scar Dechanneling. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 326-336.	2.1	200
140	T-Wave Oversensing in Patients With Brugada Syndrome: True Bipolar Versus Integrated Bipolar Implantable Cardioverter Defibrillator Leads. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 792-798.	2.1	19
141	Genetic analysis, in silico prediction, and family segregation in long QT syndrome. European Journal of Human Genetics, 2015, 23, 79-85.	1.4	16
142	Clinical interpretation of genetic variants in arrhythmogenic right ventricular cardiomyopathy. Clinical Research in Cardiology, 2015, 104, 288-303.	1.5	13
143	Sequenom MassARRAY approach in the arrhythmogenic right ventricular cardiomyopathy post-mortem setting: clinical and forensic implications. International Journal of Legal Medicine, 2015, 129, 1-10.	1.2	18
144	Stop-Gain Mutations in PKP2 Are Associated with a Later Age of Onset of Arrhythmogenic Right Ventricular Cardiomyopathy. PLoS ONE, 2014, 9, e100560.	1.1	22

#	Article	IF	CITATIONS
145	Reversal of spherical remodelling of the left atrium after pulmonary vein isolation: incidence and predictors. Europace, 2014, 16, 840-847.	0.7	23
146	<scp>EAARN</scp> score, a predictive score for mortality in patients receiving cardiac resynchronization therapy based on preâ€implantation risk factors. European Journal of Heart Failure, 2014, 16, 802-809.	2.9	59
147	Fusionâ€Optimized Intervals (FOI): A New Method to Achieve the Narrowest QRS for Optimization of the AV and VV Intervals in Patients Undergoing Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2014, 25, 283-292.	0.8	58
148	Benefit of Left Atrial Roof Linear Ablation in Paroxysmal Atrial Fibrillation: A Prospective, Randomized Study. Journal of the American Heart Association, 2014, 3, e000877.	1.6	37
149	CMR-Guided Approach to Localize and Ablate Gaps in Repeat AF Ablation Procedure. JACC: Cardiovascular Imaging, 2014, 7, 653-663.	2.3	129
150	Cardiac Rhythm Management Devices. Journal of the American College of Cardiology, 2014, 63, 1776-1777.	1.2	0
151	A missense mutation in the sodium channel $\hat{l}^2 lb$ subunit reveals SCN1B as a susceptibility gene underlying long QT syndrome. Heart Rhythm, 2014, 11, 1202-1209.	0.3	33
152	The Atrial Fibrillation Ablation Pilot Study: an European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. European Heart Journal, 2014, 35, 1466-1478.	1.0	180
153	Sinus rhythm detection of conducting channels and ventricular tachycardia isthmus in arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2014, 11, 747-754.	0.3	44
154	Risk Stratification and Treatment of Brugada Syndrome. Current Cardiology Reports, 2014, 16, 508.	1.3	16
155	Rapid palpitations: three of a kind?. Netherlands Heart Journal, 2013, 21, 472-472.	0.3	0
156	Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. International Journal of Cardiology, 2013, 168, 4093-4097.	0.8	57
157	Left Atrial Sphericity: A New Method to Assess Atrial Remodeling. Impact on the Outcome of Atrial Fibrillation Ablation. Journal of Cardiovascular Electrophysiology, 2013, 24, 752-759.	0.8	127
158	Complete atrioventricular block does not reduce longâ€term mortality in patients with permanent atrial fibrillation treated with cardiac resynchronization therapy. European Journal of Heart Failure, 2013, 15, 1412-1418.	2.9	20
159	Inappropriate ICD Shocks - When Monitoring Zones Do More Than Monitor. Indian Pacing and Electrophysiology Journal, 2013, 13, 190-193.	0.3	5
160	Combined Endocardial and Epicardial Catheter Ablation in Arrhythmogenic Right Ventricular Dysplasia Incorporating Scar Dechanneling Technique. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 111-121.	2.1	189
161	Mapping Data Predictors of a Left Ventricular Outflow Tract Origin of Idiopathic Ventricular Tachycardia With V ₃ Transition and Septal Earliest Activation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 484-491.	2.1	28
162	ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. Europace, 2012, 14, 1094-1103.	0.7	123

#	Article	IF	Citations
163	Improved Outcomes and Complications of Atrial Fibrillation Catheter Ablation Over Time: Learning Curve, Techniques, and Methodology. Revista Espanola De Cardiologia (English Ed), 2012, 65, 131-138.	0.4	11
164	Evolución de la mejora en los resultados y las complicaciones de la ablación por catéter de la fibrilación auricular: aprendizaje, técnicas y metodologÃa. Revista Espanola De Cardiologia, 2012, 65, 131-138.	0.6	28
165	Noninvasive Identification of Ventricular Tachycardia-Related Conducting Channels Using Contrast-Enhanced Magnetic Resonance Imaging in Patients With Chronic Myocardial Infarction. Journal of the American College of Cardiology, 2011, 57, 184-194.	1.2	173
166	Personalized Remote Monitoring of the Atrial Fibrillation Patients with Electronic Implant Devices. Journal of Healthcare Engineering, 2011, 2, 183-196.	1.1	5
167	Electrocardiographic versus Echocardiographic Optimization of the Interventricular Pacing Delay in Patients Undergoing Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2011, 22, 1129-1134.	0.8	48
168	Guideline-driven telemonitoring and follow-up of cardiovascular implantable electronic devices using IEEE 11073, HL7 & LT &		4
169	CardioPulse Articles. European Heart Journal, 2011, 32, 1173-1181.	1.0	5
170	Ablation of Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Dysplasia. Journal of Cardiovascular Electrophysiology, 2010, 21, 473-486.	0.8	45
171	Ultrasound Findings During Percutaneous Treatment of Bifurcated Coronary Lesions. Revista Espanola De Cardiologia (English Ed), 2008, 61, 930-935.	0.4	7
172	Usefulness of Hyperemic Venous Return Angiography for Studying Coronary Venous Anatomy Prior to Cardiac Resynchronization Device Implantation. Revista Espanola De Cardiologia (English Ed), 2008, 61, 936-944.	0.4	2
173	Late Failure of Left Ventricular Leads Stabilized Using the Retained Guidewire Technique in Patients Undergoing Cardiac Resynchronization Therapy. Revista Espanola De Cardiologia (English Ed), 2008, 61, 91-94.	0.4	2
174	Successful slow pathway ablation for atrioventricular nodal re-entrant tachycardia via a hypoplastic inferior vena cava in a patient with an azygos continuation. Europace, 2008, 10, 467-468.	0.7	9
175	Double-Wire Technique for Implanting a Left Ventricular Venous Lead in Patients With Complicated Coronary Venous Anatomy. Revista Espanola De Cardiologia (English Ed), 2007, 60, 110-116.	0.4	4
176	Serum lipids and estrogen receptor gene polymorphisms in male-to-female transsexuals: effects of estrogen treatment. European Journal of Internal Medicine, 2004, 15, 231-237.	1.0	23
177	Bone Mass, Bone Turnover, Vitamin D, and Estrogen Receptor Gene Polymorphisms in Male to Female Transsexuals. Journal of Clinical Densitometry, 2003, 6, 297-304.	0.5	28